The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! About 1.12 million shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has declined 18.61% since April 6, 2016 and is downtrending. It has underperformed by 20.57% the S&P500.
The move comes after 6 months negative chart setup for the $200.14 million company. It was reported on Nov, 8 by Barchart.com. We have $4.50 PT which if reached, will make NASDAQ:PTCT worth $26.02M less.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 EPS, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage
Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Outperform” rating by Oppenheimer on Thursday, February 25. Citigroup downgraded the stock to “Neutral” rating in Wednesday, February 24 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Outperform” rating by Wedbush on Wednesday, February 24. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by Jefferies on Friday, October 23. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, October 16 with “Outperform” rating. JP Morgan downgraded the shares of PTCT in a report on Tuesday, February 23 to “Neutral” rating. Jefferies upgraded it to “Hold” rating and $12 target price in Wednesday, February 24 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Sector Perform” rating given on Wednesday, February 24 by RBC Capital Markets. Jefferies downgraded the stock to “Underperform” rating in Wednesday, November 25 report.
According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.40, from 0.83 in 2016Q1. The ratio improved, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
The Massachusetts-based Rhumbline Advisers has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Wellington Mngmt Grp Llp, a Massachusetts-based fund reported 4.60M shares. Ladenburg Thalmann Finance Ser Inc accumulated 0% or 277 shares. Moreover, Credit Suisse Ag has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 38,386 shares. Brandywine Glob Inv Ltd Liability reported 56,851 shares or 0% of all its holdings. Springbok Cap Mgmt Limited Company owns 8,800 shares or 0.01% of their US portfolio. State Street last reported 582,348 shares in the company. Blackrock Institutional Co Na holds 812,757 shares or 0% of its portfolio. D E Shaw & owns 28,761 shares or 0% of their US portfolio. National Bank & Trust Of New York Mellon holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 150,068 shares. New York State Common Retirement Fund last reported 0% of its portfolio in the stock. Metropolitan Life Insurance Ny accumulated 23,703 shares or 0% of the stock. Alliancebernstein L P last reported 0% of its portfolio in the stock. Eagle Advsr Lc reported 28,870 shares or 0.01% of all its holdings. Citigroup Incorporated holds 0% or 15,625 shares in its portfolio.
More recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Foxbusiness.com which released: “Here’s Why PTC Therapeutics, Inc. Is Crashing Today” on November 03, 2016. Also Fool.com published the news titled: “Why PTC Therapeutics, Inc. Is Crashing Today” on October 17, 2016. Prnewswire.com‘s news article titled: “PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial …” with publication date: October 19, 2016 was also an interesting one.
PTCT Company Profile
PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.